SEC Company Response from Moleculin Biotech, Inc. (MBRX) (CIK 0001659617) (MBRX) — Aug 18, 2017
Moleculin Biotech, Inc. (MBRX) (CIK 0001659617)
Date: Aug. 18, 2017 · CIK: 0001659617 · Accession: 0001144204-17-044095
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-219434
Letter
Securities and Exchange Commission Division of Corporation Finance Office of Healthcare & Insurance Attention: Christine Westbrook, Esquire Re: Moleculin Biotech, Inc. Registration Statement on Form S-3 File No. 333-219434 Request for Acceleration of Effective Date
Dear Ms. Westbrook:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Moleculin Biotech, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Shelf Registration Statement on Form S-3 and declare the Shelf Registration Statement effective as of 4:30 PM, Eastern Time, on August 21, 2017, or as soon thereafter as possible.
In connection with this request for acceleration, the Company acknowledges that:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
Moleculin Biotech, Inc.
Show Raw Text
CORRESP
1
filename1.htm
MOLECULIN
BIOTECH, INC.
2575
West Bellfort, Suite 333
Houston, Texas 77054
August 17, 2017
By EDGAR Submission
Securities and Exchange Commission
Division of Corporation Finance
Office of Healthcare & Insurance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Christine Westbrook, Esquire
Re: Moleculin Biotech, Inc.
Registration Statement on Form
S-3
File No. 333-219434
Request for Acceleration of Effective
Date
Dear Ms. Westbrook:
Pursuant to Rule 461
of the General Rules and Regulations under the Securities Act of 1933, as amended, Moleculin Biotech, Inc. (the “Company”)
hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the
above-referenced Shelf Registration Statement on Form S-3 and declare the Shelf Registration Statement effective as of 4:30 PM,
Eastern Time, on August 21, 2017, or as soon thereafter as possible.
In connection with
this request for acceleration, the Company acknowledges that:
· should
the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission
from taking any action with respect to the filing;
· the action
of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the
Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company
may not assert staff comments and the declaration of effectiveness as defense in any proceeding initiated by the Commission or
any person under the federal securities laws of the United States.
Sincerely,
Moleculin Biotech, Inc.
/s/ Jonathan Foster
By: Jonathan Foster
Title: Chief Financial Officer and Executive Vice President